The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity.
Ahmad A. Tarhini
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
William A LaFramboise
No relevant relationships to disclose
Patricia Petrosko
No relevant relationships to disclose
Christopher G Deamont
No relevant relationships to disclose
John M. Kirkwood
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb